Clinical and histopathological activity in paucibacillary leprosy patients after fixed-duration multidrug therapy

Leprosy Review

Volumn 68, Issue 3, 1997, Pages 218-224

  Ebenezer, G J ^a   Suneetha, S ^a   Arunthathi, S ^a  

^a Schieffelin Leprosy Res/Train Ctr   (India)

Author keywords

[No Author keywords available]

Indexed keywords

LEPROSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEPROSY; MALE; SCHOOL CHILD; SKIN BIOPSY;

EID: 0030687660     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: 10.5935/0305-7518.19970030     Document Type: Article

References (22)

1. Treatment of paucibacillary leprosy. In chemotherapy of leprosy for control programmes. Report of a WHO group. WHO Tech Rep Ser, 1982; 675: 24.
2. WHO Expert Committee on leprosy. Sixth report. Tech Rep Ser, 1988; 768: 1.
3. Recent trends in chemotherapy of paucibacillary leprosy, ICMR Bulletin; 1990, 20: (6).
4. Ridley DS & Jopling WH. Classification of leprosy according to immunity. A five group system. Int J Lepr, 1966; 34: 255-73.
5. Khanolkar VR. Method of taking biopsy tissue for histopathological examination. Lepr Rev, 1951; 22: 83-85.
6. Job CK and Chacko CJG. A modification of Fite's stain for demonstration of M. leprae in tissue sections. Int J Lepr, 1986; 58: 70-80.
7. Nilsen R, Mengistu G & Reddy BB. The role of nerve biopsies in the diasnosis and management of leprosy. Lepr Rev. 1989; 60: 28-32.
8. Sehgal VN, Rege VL & Reys M. Correlation between clinical and histopatbological classification in leprosy. Int J Lepr, 1977; 45: 278-280.
9. Srinivasan H, Rao KS & Iyer CGS. Discrepancy in the histopathological features of leprosy lesions in the skin and peripheral nerve. Lepr Ind, 1982; 54: 275-282.
10. Katoch K, Ramu G, Ramanathan U & Desikan KV. Comparison of three regimens containing rifampicin of paucibacillary leprosy patients. Int J Lepr, 1987; 62: 98-103.
11. Kumar B, Kaur S and Kaur I. Histological evaluation and follow up study of short term combination therapy for paucibacillary leprosy. Ind J Lepr, 1987; 59: 54-62.
12. Revankar CK, Ganapati R & Naik DD. Multidrug therapy for paucibacillary leprosy. Experience in Bombay. Ind J Lepr, 1985; 57: 773-779.
13. Beovinger G, Ponnighaus JM and Fine PEM. Preliminary appraisal of WHO recommended multidrug regimen in paucibacillary patients in Malawi. Int J Lepr, 1988; 56: 408-417.
14. Ramu G. Duration of MDT for paucibacillary leprosy. Ind J Lepr, 1992; 64: 1-7.
15. Lowe J. The sulfone treatment of tuberculoid leprosy. Int J Lepr, 1950; 18: 457-468.
16. Turk JL & MFR (1978) Leprosy. In: Immunological diseases 3rd ed., Boston, Samter M, Little Brown and Company, 627-638.
17. Job CK. Pathology of Leprosy. In Leprosy. Edited by Hastings RC. 2nd ed., Churchill Livingstone, (1994): 199-200.
18. Katoch K, Ramanathan U, Natarajan M, Bagga AK, Bhatia AS, Saxena RK & Ramu G. Relapses in paucibacillary patients after treatment with 3 short-term regimens containing rifampicin. Int J Lepr, 1989; 57: 458-464.
19. Pavithran K. Relapse of paucibacillary leprosy after short course multidrug therapy. Ind J Lepr, 1988; 60: 225-229.
20. Ekambaram V & Rao MK. Relapse rate in paucibacillary leprosy patients after multidrug therapy in North Arcot District. Ind J Lepr, 1991; 63: 34-42.
21. Revankar CR, Karjivkar VG, Gurav VJ & Ganapathi R. Clinical assessment of paucibacillary leprosy under multidrug therapy - three years follow up study. Ind J Lepr, 1989, 61: 355-359.
22. The leprosy Unit, WHO. Risk of relapse in leprosy. Ind J Lepr, 1955; 67: 13-26.